Department of Orthopaedic and Trauma Surgery, Lucerne Cantonal Hospital, 6000, Luzern 16, Switzerland.
Department of Trauma and Reconstructive Surgery, University Hospital RWTH Aachen, Aachen, Germany.
Int Orthop. 2021 Sep;45(9):2355-2363. doi: 10.1007/s00264-021-05157-4. Epub 2021 Aug 6.
To assess which pre-operative parameters correlate with wound revisions after an extended lateral approach to the calcaneus.
Pre-operative laser-Doppler spectrophotometry was applied in patients undergoing open reduction and internal fixation. The number of wound revisions was recorded during pos-toperative follow-up. Spearman rho analysis was used to identify factors associated with wound revision and receiver operator characteristics curves were calculated for the identified factors.
Thirty-four patients (29 men, 5 women; 37 calcanei) with a mean patient age of 43 ± 14 years were analyzed. The minimal oxygen saturation value at the five measurement locations as well as the minimal value for flow correlated negatively with wound revisions (p value = 0.025 and 0.038, respectively). The area under the curve for the pre-operative minimal value of oxygen saturation was 0.841 (95%CI 0.64-1.00, p = 0.028), indicating a good accuracy as a test to predict wound revision.
A pre-operative oxygen saturation of at least 20.5% across five measurement points along the anticipated incision identified all patients not needing a wound revision (negative predictive value 100%). On the other hand, patients with at least one measurement below 20.5% were at risk for wound revision surgery (sensitivity 100%, specificity 48.5%). ClinicalTrials.gov NCT01264146.
评估在跟骨外侧延长入路切开复位内固定术后,哪些术前参数与伤口翻修相关。
对行切开复位内固定术的患者应用术前激光多普勒光谱仪。在术后随访期间记录伤口翻修的次数。采用 Spearman rho 分析来确定与伤口翻修相关的因素,并计算所确定因素的受试者工作特征曲线。
共分析了 34 例(29 名男性,5 名女性;37 例跟骨)患者,平均年龄 43 ± 14 岁。五个测量部位的最小氧饱和度值以及最小血流值与伤口翻修呈负相关(p 值分别为 0.025 和 0.038)。术前最小氧饱和度值的曲线下面积为 0.841(95%CI 0.64-1.00,p=0.028),表明作为预测伤口翻修的测试,其准确性较好。
预期切口沿线五个测量点的氧饱和度至少达到 20.5%可确定所有无需行伤口翻修的患者(阴性预测值 100%)。另一方面,至少有一个测量值低于 20.5%的患者有伤口翻修手术的风险(敏感性 100%,特异性 48.5%)。ClinicalTrials.gov NCT01264146。